Allogeneic HSCT in Elderly

Allogeneic HSCT in elderliesa chimera?

Didier Blaise, MDAUBOH 2015, Bangkok

August 28th, 2015

Epidemiology

70 %

Smith,JCO 2009

AML in elderlies…5-year relative survival rates with

respect to age in patients with AML1

0

10

20

30

40

50

%

Age, years <45 45–54 65+55–64

1. Howlader N, et al (eds). SEER Cancer Statistics Review, 1975-2008 (2010); available at http://seer.cancer.gov/csr/1975_2008/

2. Appelbaum FR et al, Hematology Am Soc Hematol Educ Program 2001:62–86

OS in patients aged >55 years (ECOG data from 1973–1997)2

4y à 48 %

4y à 37 %

4

Allogeneic HSCT in elderlies• Needs to address

– Specific approaches• Conditioning• Graft• Donor

– Patient selection

5

RIC=Reduced intensity conditioning14 patients (2001-2003)Age : 62RICSibling :13/MUD : 1

6

Long-term Outcome372 patients (98-08)Age : 64 [60-75]HLA identical 91 %NMAC : Flu5/TBI2HCT-CI>3:47%

Sorror, JAMA 2011

5y 27% 5y 41% 5y 35%

Results need improvement

Age ≠ Prognostic

7

Prospective phase II clinical trialRIC MRD Allo HSCT

over the Age of 55 Years

75 patients

Age :60 [55-70]

Hematologic Malignancies

HLA Ident Sib

RIC : Flu5-Bu2-ATG2

Blaise, Haematologica 2015

2y 36 %

1y 9 %

2y 67 %

2y 51 %

8

RIC MRD Allo HSCT over the Age of 55 Years

2y 36 %

1y 9 %

2y 67 %

2y 51 %

9

75 patients

Age :60 [55-70]

Hematologic Malignancies

HLA Ident Sib

RIC : Flu5-Bu2-ATG2N NRM P OS P

Age< 60≥ 60

3342

12 %17 %

0,650 61%45%

0,579

Karnofsky index90-100≤80

4819

7%26%

0,020 42%56%

0,146

HCT-CI0-2≥ 3

2647

20%13%

0,514 39%62%

0,094

Disease risk indexLowIntermediateHigh/Very High

85312

13% 9%25%

0,500 88%56%31%

0,041

10

Patients reporting an impaired EORTC score one year after HSCT

Pain

Fatigue

Social Functining

Cognitive Functioning

Emotional Functioning

Physical Functioning

Role Functioning

Global Quality of Life

-40% -20% 0% 20% 40% 60% 80% 100%

81.3%

70.6%

75.0%

71.4%

82.4%

81.2%

63.2%

75.0%

Situation impaired when compared to day -6 Situation equal or not impaired when compared to day-6

RIC MRD Allo HSCT over the Age of 55 Years

Blaise D, et al. Haematologica 2015

• Patients (n=516)– Period: 2008-2012 – Median age at allo-HSCT: 63 years (range: 60-74)– Disease: Myeloid disorders (65%), Lymphoid disorders (35%) – Donors: HLA matched unrelated donors (URD) (96%) – RIC regimen: Fludarabine-based (91%)]– Stem cells source: PBSC (92%)– Disease status at allo-HSCT: early (65%), advanced (35%)– EBMT score: 75% with score ≥ 2– GVHD prophylaxis: CSA + MMF (47%), CSA + methotrexate (20%)

• No statistical difference between the group of patients with age < 65 years (60-65), N=374 (72%) and patients with age ≥ 65 years, N=142 (28%).

Allogeneic HSCT after RIC for patients ≥ 60 years with hematological malignancies using unrelated donors

Progression-Free Survival

Allo-HSCT in elderly patients

• PFS at 2 years:– Group ≤ 65 years: 42% (37-47), median = 14.5 months – Group > 65 years: 47% (39-56), median = 16.6 months

p=0.60

≤ 65 years> 65 years

Allo HSCT beyond 60 years: Institut Paoli Calmettes

• 2005 to 2014 • 263 patients• Median Fup:34 months

13

Age (médiane, extrêmes)

63 (60-72)

60-65 190 (72%)

65-70 65 (25%)

>70 8 ( 3%)

Sexe Femme 111 (42%)

Homme 152 (58 %)

HCT-CI ≥3 120 (45 %)

Diagnosis

ACUTE LEUKEMIA 95 (36%)AML 84

ALL 8

MIXTE 3

CML 4

CLL 13

LPC 1

LYMPHOMA 53 (20 %)NHL 51

HD 2

MULTIPLE MYELOMA 37 (14 %)MDS 41 (15 %)MYELOFIBROSIS 11

MDS/PMS 8

Disease Risk Index (DRI)Low 51(19 %)Intermediate 160(61 %)High/Very High 52(20 %)

SourcePBSC 234 (89%)

BM 9 ( 3%)

Cord Blood 17 ( 6%)

PBSC+BM 3 ( 1%)

Compatibilité HLAHLA Id Sibling 106 (40%)

MUD 97 (37%)

MMUD 28 (10%)

Haplo 32 (12 %)

ConditionnementNMAC 70 (26 %)

RIC 177 (67 %)

RTC 16 ( 6 %)

15

GVH aigue II-IV 31 %III-IV 15 %

GVH chronique

Limitée/extensive 27%

Extensive 18 %

GVHD

16

HLA identical HSCT in 205 patients

17

J100 9%

1 an 23%

3 ans 28%

0 1 2 3 4 5

0.0

0.2

0.4

0.6

0.8

1.0

20560

12727

9515

689

404

244

0 1 2 3 4 5

0.0

0.2

0.4

0.6

0.8

1.0

20560

11324

7615

518

323

223

0 1 2 3 4 5

0.0

0.2

0.4

0.6

0.8

1.0

20560

11324

7615

518

323

223

0 1 2 3 4 5

0.0

0.2

0.4

0.6

0.8

1.0

20560

11324

7615

518

323

223

No différence!

OS

PFS

RINRM

HLA id Non HLA id

18

HLA id HSCT in 205 pts

HLA identical Donors in elderlies?

- elderly- Comorbidities: frequent contra-indication for donation- Clonal hematopoiesis?

19

What about siblings?

%

Genovese, NEJM 2014 20

21

Alternative Donors? Haplo-ID HSCT

Retrospective Study of 2 strategies• Patients– Age > 55 years– High risk hematologic malignancies

• Innovation: Haplo HSCT patients : N=31– 5 to 2 Ag MM– Negative DSA– Modifications according to learning process: Graft, CDT

• Standard: UD and MRD: N= 47+63– Same period– 9 or 10/10– RIC: F5-BX2-ATG2

22

HaploN 31

Median age 62 (56-73)HCT-CI > 2 58%Myeloid Malignancies 48%Active Disease 39%High/Very High DRI 35%CDT NMAC RIC TT-RTCF5BX2S2

21 (68%)6 (19%)4 (12%)

PBSCT 87%

HLA sibN 47

UDN 63

62 (55-71) 64 (60-68)55% 49%46% 51%

40% 30%25% 27%

100% 100%

100% 95%

23

HaploN 31

Graft Failure 13-4 aGVHD 10%Ext cGVHD 0%NRM 9%Relapse 28%2y OS 70%2y PFS 67%2y PFS w/o ext cGVHD 67%

HLA sibN 47

UDN 63

0 013% 25%11% 15%10% 36%28% 29%77% 51%64% 38%51% 31%

Comparison of 2 allo HSCT strategies for patients older than 55 years and lacking MRD

• Primary Question– One year DFS w/o ext cGVHD

• Starting time: – Day of no MRD

• Population– High risk hematologic malignancies

• Numbers: 54 patients per arm• Secondary questions

– other– QOL – Economic evaluation

24

• Prospective Study– HAPLO

• F5Bx2• Thiothepa: 5mg• HD Cy post HSCT• CyA+MMF

– MUD 10/10 and 9/10• F5Bx2• ATGx2• CyA+MMF

• Graft– PBSC

Conclusion• Feasibility of allo HSCT in elderly• No more GVHD! • HLA id is not a prerequisite!

• Needs– Better antitumoral activity– Lower toxicity by tailoring approach

25

26

• Eligibility• Age 55-65 or Cormorbidities• Poor prognosis AML/MDS• HLA identical RD or UD

• Primary endpoint : 2 year PFS• Sample size: 177 patients

• Quality of life study• Economics• Non interventional PK• BX Pharmacogenomics

National Prospective Trial on dose intensity of conditioning

NCT0198506

DonorConditioning

Patient

-3 -2 -1-4-6 -5 0

GVHD prophylaxis

Chimerism

Individualized Immunotherapy

• Cellular therapy: DLI, NK-DLI , Treg• Tumor Antigen vaccination: WT1…• Post graft drugs: Aza, Lenalidomide,

anti-NKG2A moab…• CAR-T? Checkpoint inhibitors?

Allo-HSCT

Disease

Relapse

27

Importance of Geriatric assessment

Muffly,Haematologica;2014 28

Oncogeriatric evaluationSelection and care…

29

• Since 2012• Patients > 65 years• With Geriatric MDs- Pre-HSCT, 3 m, 1 y

Therapeutic Education Program (TEP)

• Labelized TEP• To improve OS and QOL

30

Conclusion• Allo HSCT in elderly is achievable• Better outcome to be achieved if needs and reality of this population

taken into account

31

32

Collaborations– FB Petersen, Intermountain HC, SLC– M Mohty, St Antoine, Paris– B Andersson, MD Anderson, Houston– L Luznick, E Fuchs, Johns Hopkins, Baltimore